Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings, Inc. reports developments around cell engineering, autonomous laboratory infrastructure, and contract research services that make biological R&D more programmable. Its updates cover Ginkgo Cloud Lab, Datapoints and Solutions services, Reconfigurable Automation Carts, Catalyst automation software, and AI-enabled workflows for protein engineering, nucleic acid design, cell-free systems, and biological manufacturing.
Company news also includes financial-results presentations, customer and research collaborations, agricultural biotechnology manufacturing work, and capital or governance updates. Following the completed divestiture of its Biosecurity business, recurring coverage centers on Ginkgo's autonomous lab strategy, remote wet-lab access, microbial strain engineering, fermentation processes, and the commercial use of lab-generated biological data.
Ginkgo Bioworks (NYSE: DNA) announced that Co-Founder and CEO Jason Kelly will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 10:30 a.m. PT / 1:30 p.m. ET.
Investors can access presentation materials and slides on the company's investor relations events page at the time of posting.
Ginkgo Bioworks (NYSE: DNA) announced a partnership with Carnegie Mellon University on an ARPA-H award for the POSEIDON program (Platform Optimizing SynBio for Early Intervention and Detection in Oncology) dated December 22, 2025. Ginkgo will serve as Commercial Partner while CMU leads the project under principal investigator Rebecca Taylor.
The program aims to develop an orally administered pill with engineered tumor-targeting sensors plus a user-friendly at-home urine screening device. The multidisciplinary team includes researchers from University of Pittsburgh, UMass Amherst, KU Leuven, and corporate partners Velentium Medical, Clinical Research Strategies, and Platypus Bio.
Ginkgo Bioworks (NYSE: DNA) and Agricen announced on Dec 17, 2025 the completion of an initial collaboration to develop and optimize a low-cost, efficient fermentation process for complex bacterial strains used in an Agricen soil amendment product.
The work reduced fermentation time for challenging microbes, freed Agricen to focus on pipeline development, and demonstrated Ginkgo's platform capabilities from small screening through commercial volumes of 20 L to 3,000 L.
Ginkgo Bioworks (NYSE: DNA) announced a partnership with Deep Origin on a 4.5-year, ARPA-H funded CATALYST project called PREDICTS to develop a computational platform for drug safety.
Ginkgo will use its Datapoints platform to generate high-throughput, structured datasets for AI model training using small-molecule and genetic perturbations across multiple cell and tissue types. Planned readouts include cell type-specific toxicity endpoints, DRUG-seq transcriptomics, and cell painting.
The collaboration aims to support safer therapeutics through multi-omics data generation and in vitro models integrated with AI over the project term.
Ginkgo Bioworks (NYSE: DNA) was awarded a four-year, up to $47M contract by Pacific Northwest National Laboratory's EMSL to co-design, build, and integrate a High‑Throughput Automated Phenotyping Platform (HTP‑APP) for the DOE Microbial Molecular Phenotyping Capability (M2PC).
The modular HTP‑APP will use Ginkgo Automation's Catalyst scheduling software and Reconfigurable Automation Carts (RACs) to automate end‑to‑end workflows, support BSL‑2 operations, enable remote cloud‑lab planning, and generate multimodal data intended for AI/ML analysis.
STRM.BIO (DNA) was awarded an ARPA-H EMBODY contract on Dec 3, 2025 with up to $8.4 million to support a first-phase program advancing its proprietary megakaryocyte-derived extracellular vesicle (MV) delivery platform for in vivo cell and gene therapy.
STRM.BIO will act as prime, partnering with Ginkgo (DNA), the University of British Columbia, and Advanced Bioprocess Services to develop bone marrow-targeted in vivo CAR-T therapeutics using MV delivery and self-amplifying RNA expertise.
Ginkgo Bioworks (NASDAQ:DNA) is partnering on an Illinois-led team to develop new treatments for oral health—combining scientific expertise and collaborative research to advance therapeutic options.
The initiative aims to accelerate development through shared resources, preclinical work, and potential clinical pipelines, positioning the team to address unmet needs in oral disease management.
Key highlights include cross-institution collaboration, an emphasis on translational research, and planned steps toward clinical validation and commercialization.
Ginkgo Bioworks (NYSE: DNA) reported third quarter 2025 results on November 6, 2025: Total revenue $39M (down 56% year‑over‑year, prior year included $45M non‑cash deferred revenue), Cell Engineering $29M, Biosecurity $9M. GAAP net loss was $81M and Adjusted EBITDA was $(56)M. Cash, cash equivalents and marketable securities were $462M as of September 30, 2025.
Company reaffirmed full‑year 2025 guidance: Total revenue $167–$187M, Cell Engineering $117–$137M, Biosecurity at least $40M. Business highlights include a multi‑year extension with Bayer and a BARDA project award up to $22.2M. A webcast and replay are available for investors.
Ginkgo Bioworks (NYSE: DNA) was awarded a BARDA BioMaP-Consortium project agreement on November 3, 2025 to develop cost-reducing, scalable domestic biomanufacturing innovations for monoclonal antibodies (mAbs) against filoviruses such as Ebola (EBOV) and Sudan virus (SUDV).
The contract value is up to $22.2 million. Ginkgo will lead a partner team (Advanced BioScience Laboratories, Isolere Bio by Donaldson, NeuImmune, and ProteoNic) to integrate technologies across the mAb production process and to produce an anti-filovirus mAb cocktail (1C3 and 1C11) discovered at Emory University. The project is funded in whole or in part by BARDA/ASPR under OT number 75A50123D00003.
Ginkgo Bioworks (NYSE: DNA) announced an extension of its multi-year strategic partnership with Bayer on Oct 31, 2025 to continue joint R&D on agricultural biologicals, including microbial nitrogen fixation. The collaboration, which began in 2017, keeps Bayer's right to commercialize resulting biological products as complements to synthetic fertilizers.
Ginkgo will continue independent partnerships and advance its agricultural biologicals platform, which includes an R&D site in West Sacramento.